Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens.

In this observational cohort study, the objective was to compare low-density lipoprotein (LDL) cholesterol dynamics in people with HIV (PWH) who switched to a regimen containing doravirine (DOR), rilpivirine, dolutegravir, or bictegravir and were naïve to the studied drugs. Generalized additive mixed models were used to examine LDL cholesterol dynamics. LDL cholesterol was measured in 2381 PWH: during the first two years, DOR had the greatest lowering effect and showed the most favorable lipid outcome.